What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Internal medicine
Kapil N. Bhalla mainly focuses on Cancer research, Apoptosis, Programmed cell death, Myeloid leukemia and Histone deacetylase inhibitor.
Kapil N. Bhalla does research in Cancer research, focusing on Imatinib mesylate specifically.
His work carried out in the field of Apoptosis brings together such families of science as Molecular biology, Cancer and Cell biology.
In Programmed cell death, Kapil N. Bhalla works on issues like Mitochondrion, which are connected to Warburg effect and Glycolysis.
His work deals with themes such as Cell culture and Leukemia, which intersect with Myeloid leukemia.
His Histone deacetylase inhibitor study incorporates themes from Hypokalemia, Histone methyltransferase, Panobinostat and EZH2.
His most cited work include:
- Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked (4420 citations)
- Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL (1118 citations)
- Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. (666 citations)
What are the main themes of his work throughout his whole career to date?
Kapil N. Bhalla focuses on Cancer research, Apoptosis, Molecular biology, Internal medicine and Leukemia.
A large part of his Cancer research studies is devoted to Myeloid leukemia.
His research on Apoptosis often connects related topics like Cancer cell.
His work is dedicated to discovering how Molecular biology, Cell culture are connected with Cytotoxicity and other disciplines.
His studies deal with areas such as Gastroenterology, Oncology and Pharmacology as well as Internal medicine.
Kapil N. Bhalla works mostly in the field of Imatinib, limiting it down to topics relating to Chronic myelogenous leukemia and, in certain cases, Imatinib mesylate.
He most often published in these fields:
- Cancer research (52.69%)
- Apoptosis (21.07%)
- Molecular biology (19.83%)
What were the highlights of his more recent work (between 2015-2021)?
- Cancer research (52.69%)
- Myeloid leukemia (14.67%)
- Leukemia (15.29%)
In recent papers he was focusing on the following fields of study:
Kapil N. Bhalla mainly investigates Cancer research, Myeloid leukemia, Leukemia, Internal medicine and RUNX1.
His Cancer research study integrates concerns from other disciplines, such as BRD4, Progenitor cell, Apoptosis, Transcription factor and Diffuse large B-cell lymphoma.
The Survivin research Kapil N. Bhalla does as part of his general Apoptosis study is frequently linked to other disciplines of science, such as PIM1, therefore creating a link between diverse domains of science.
Within one scientific family, Kapil N. Bhalla focuses on topics pertaining to Genomics under Myeloid leukemia, and may sometimes address concerns connected to Computational biology.
His study on Leukemia also encompasses disciplines like
- Myeloid which intersects with area such as Myeloproliferative neoplasm,
- Ruxolitinib together with KDM1A.
His Internal medicine study combines topics in areas such as Gastroenterology and Oncology.
Between 2015 and 2021, his most popular works were:
- Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies (178 citations)
- Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells (85 citations)
- BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. (75 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
The scientist’s investigation covers issues in Cancer research, Leukemia, Myeloid leukemia, Internal medicine and Myeloid.
The study incorporates disciplines such as Apoptosis, Germline and Bromodomain, BRD4 in addition to Cancer research.
In his research, MCL1 and Cyclin-dependent kinase 6 is intimately related to Progenitor cell, which falls under the overarching field of Apoptosis.
His research investigates the connection with Leukemia and areas like Antagonist which intersect with concerns in Histone deacetylase inhibitor, KDM1A, Cell Cycle Protein, RNA-binding protein and Nuclear protein.
The various areas that Kapil N. Bhalla examines in his Myeloid leukemia study include Mutation, Genomics, Somatic evolution in cancer, Hypomethylating agent and DNA sequencing.
His Internal medicine research includes elements of Gastroenterology and Oncology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
